Time point | Study period | ||||
Enrolment | Allocation | Postallocation | Close-out | ||
D0-21 | D0-14 | D0 | M1 | M3 | |
Enrolment | |||||
Eligibility screen | X | ||||
Informed consent | X | ||||
Allocation | X | ||||
Interventions | |||||
Start of treatment | X | ||||
End of treatment | X | ||||
Surgery | X | ||||
Blood test | X | X | X | ||
Urine test | X | X | |||
Delivery of pain diary | X | ||||
Assessments | |||||
Numeric Rating Scale | X | X | X | ||
Neuropathic Pain Questionnaire in 4-Questions Neuropathic Pain Symptom Inventory | X | X | X | ||
McGill Pain Questionnaire | X | X | X | ||
Trail-Making Test | X | X | X | ||
Functional Assessment of Cancer Therapy-Cognitive Function | X | X | X | ||
EORTC QLQ-C30 | X | X | X | ||
Depression Anxiety Stress Scale | X | X | X | ||
Pittsburgh Sleep Quality Index | X | X | X | ||
Patient Global Impression of Change | X | X | X | ||
Concomitant analgesic treatments | X | X | X | X | X |
Adverse events | X | X | X | X |
EORTC QLQ C30, European Organization for Research and Treatment of Cancer Quality of Life Core 30-item.